Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals' stock experienced a surge in August 2025 due to strong earnings and anticipation of regulatory approval for TNX-102 SL. In December 2025, the stock lost value due to a dilutive registered direct offering. Clinical trial updates have resulted in an average stock movement of 4.11%. Analysts have an average twelve-month stock price forecast of $70.00 for Tonix Pharmaceuticals.

There is no explicit indication of demand seasonality for Tonix Pharmaceuticals Holding Corp.'s products and services. Demand is likely driven by medical need and regulatory approvals rather than seasonal patterns.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics and vaccines for human diseases. The company's portfolio targets central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. Key products include TONMYA™ for fibromyalgia, Zembrace® SymTouch® and Tosymra® for acute migraine, TNX-801 as a potential vaccine for smallpox and monkeypox, TNX-1800 as a COVID-19 vaccine candidate, TNX-1500 for immune-related conditions, TNX-1900 for cardiometabolic syndromes, TNX-2900 for rare diseases like Prader-Willi syndrome, TNX-4800 as an antiviral program, and TNX-3900 and TNX-4000 as upcoming broad-spectrum oral antivirals.

Tonix Pharmaceuticals is headquartered in Chatham, New Jersey. It has facilities in Massachusetts for vaccine development and manufacturing, Hamilton, Montana for vaccine production, and Frederick, Maryland for infectious disease research and development.

Tonix Pharmaceuticals has a consensus "Hold" rating from analysts, with an average rating score of 2.33. MarketBeat's MarketRank™ scored Tonix Pharmaceuticals higher than 41% of companies evaluated. The company launched the "Move Fibro Forward" campaign to enhance its reputation and patient outreach. A dilutive stock offering in December 2025 could have been perceived negatively by existing shareholders.

Approximately 13.12% of Tonix Pharmaceuticals' stock is owned by institutional investors, 0.04% by insiders, and 86.85% by public companies and individual investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Point72 Asset Management, L.P.